TRACE-AANCT07930793
Aplastic Anemia Life-Course Cohort Study
Free. We email you which fields changed when ClinicalTrials.gov updates this record.
Record History
All 1 version: 1 with changes below.
- Study First Submitted
Endpoints
Primary
Arms and interventions
1. Describe real-world treatment patterns and clinical outcomes in AA, including IST, HSCT, and other therapies. 2. Evaluate treatment-related adverse events and safety, particularly complications of ATG/ALG-based IST and HSCT. 3. Characterize longitudinal hematopoietic and immune reconstitution after drug therapy or HSCT, including immune-cell subsets, clonal T cells, immune biomarkers, and hematopoietic recovery. 4. Estimate the cumulative incidence and trajectories of clonal hematopoiesis after IST, including cytogenetic and molecular abnormalities and PNH clones. 5. Assess prognosis, including treatment discontinuation, relapse, clonal evolution, quality of life, and long-term survival.
Other: A combined retrospective and prospective observational follow-up
Sites
1 site in 1 country
- Red Blood Cell Diseases Center and Regenerative Medicine CenterTianjin, Tianjin Municipality, China